Takeda Reports P-IIb Trial Results TAK-279 for the Treatment of Plaque Psoriasis
Shots:
- The P-IIb trial (NDI-034858) evaluating TAK-279 vs PBO in a ratio (1:1:1:1:1) in 259 patients. The study met its 1EPs & 2EPs i.e., patients treated with TAK-279 (5/15/30mg, qd) achieved PASI 75 (44%/68%/67% vs 6%), PASI 90 (21%/45%/46% vs 0%) and PASI 100 (10%/15%/33% vs 0%), PGA scores of 0/1 (27%/49%/52% vs 4% or 0 (10%/15%/33% vs 0% at 30mg), respectively @12wks.
- No differences in PASI or PGA response rates were reported at 2mg (18%/2%/10%/2%) in PASI 75/PASI 100/PGA 0/1/PGA 0, respectively, frequency of AEs was 53-62% vs 44%, 2 serious AEs were seen in 1 patient (15mg) & were considered unrelated
- The company plans to initiate a P-III study of TAK-279 in PsO & the P-IIb results for PsA in FY2023 while the therapy will also study in SLE & IBD
Ref: Businesswire | Image: Takeda
Related Post:- Takeda Reports Results of Vedolizumab in P-III Trial for the Prevention of Intestinal aGvHD in Patients Undergoing allo-HSCT
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
